Top Page
GlaxoSmithKline (GSK) vs. S&P 500 (SPY)
GlaxoSmithKline Business Overview & Revenue Model
GlaxoSmithKline Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 31.38B | 30.33B | 29.32B | 34.11B | 34.10B | Gross Profit |
| 22.33B | 21.76B | 19.77B | 22.51B | 22.39B | EBIT |
| 4.02B | 6.75B | 6.43B | 6.20B | 7.78B | EBITDA |
| 6.67B | 9.14B | 8.63B | 7.76B | 10.16B | Net Income Common Stockholders |
| 2.58B | 4.93B | 4.92B | 4.38B | 5.75B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 3.71B | 5.69B | 7.88B | 4.33B | 6.37B | Total Assets |
| 59.46B | 59.01B | 60.15B | 79.10B | 80.43B | Total Debt |
| 16.99B | 18.02B | 20.99B | 24.17B | 27.15B | Net Debt |
| 13.29B | 15.08B | 17.26B | 19.90B | 20.86B | Total Liabilities |
| 46.38B | 46.21B | 50.05B | 57.76B | 59.62B | Stockholders Equity |
| 13.67B | 13.35B | 10.60B | 15.05B | 14.59B |
| Cash Flow | Free Cash Flow | |||
| 3.57B | 4.42B | 5.14B | 5.02B | 6.20B | Operating Cash Flow |
| 6.55B | 6.77B | 7.40B | 7.95B | 8.44B | Investing Cash Flow |
| -1.23B | -1.59B | -8.77B | -1.78B | 2.16B | Financing Cash Flow |
| -4.73B | -5.64B | 823.00M | -7.59B | -10.13B |
GlaxoSmithKline Technical Analysis
GlaxoSmithKline Risk Analysis
GlaxoSmithKline Peers Comparison
GlaxoSmithKline Earnings Call Summary
GlaxoSmithKline Corporate Events
GSK plc has announced the purchase of 547,800 of its own ordinary shares, as part of its ongoing buyback program, through its broker Citigroup Global Markets Limited. This transaction, executed on March 4, 2025, is part of a non-discretionary agreement and reflects the company’s strategy to manage its capital structure, potentially impacting shareholder value and market perception.
GSK has announced the repurchase of 547,800 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This move is part of a strategic effort to manage its capital structure and enhance shareholder value, with the shares being held in treasury. The company now holds a total of 174,109,205 shares in treasury, with 4,141,068,225 shares in issue, excluding treasury shares, impacting the total number of voting rights available to shareholders.
GSK announced the purchase of 537,500 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. The shares, bought at prices ranging from 1,469.00p to 1,495.00p, will be held as treasury shares. This move is part of a strategic effort to manage capital and enhance shareholder value, reflecting GSK’s commitment to maintaining a robust financial position and potentially impacting its market valuation positively.
GSK has filed its 2024 Annual Report on Form 20-F with the SEC, which includes audited financial statements for the year ending December 31, 2024. The report is accessible online, and shareholders can request a hard copy. This filing is a routine disclosure that provides transparency and accountability to shareholders and stakeholders, reinforcing GSK’s commitment to regulatory compliance and financial transparency.
GSK plc has announced its total voting rights and capital structure as of February 28, 2025. The company reported an issued share capital of 4,315,177,430 shares, with 173,023,905 shares held in treasury, resulting in a total of 4,142,153,525 voting rights. This information is crucial for shareholders to determine their interests under the Financial Conduct Authority’s rules, impacting their decision-making and compliance obligations.
GSK announced that the US FDA has accepted the Biologics License Application for depemokimab, a monoclonal antibody targeting IL-5, for review as a treatment for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, depemokimab will be the first ultra-long-acting biologic with a six-month dosing regimen, potentially reducing the burden on patients and healthcare systems. The SWIFT and ANCHOR trials demonstrated depemokimab’s efficacy in reducing asthma exacerbations and nasal polyp size, highlighting its potential to improve patient care and adherence to treatment.
GSK plc has announced the repurchase of 542,550 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, completed on February 28, 2025, is part of a non-discretionary agreement and contributes to the company’s strategy of managing its capital structure. The shares will be held in treasury, impacting the total number of voting rights and potentially affecting shareholder interests in line with the Financial Conduct Authority’s rules.
GSK announced positive results from its ANCHOR-1 and ANCHOR-2 phase III trials for depemokimab, a monoclonal antibody targeting IL-5, in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated significant improvements in nasal polyp size and obstruction with a twice-yearly dosing regimen. These findings, presented at the AAAAI/WAO Joint Congress and published in The Lancet, highlight depemokimab’s potential as an alternative to current treatments, which often require repeat surgeries and long-term corticosteroid use. The results could impact regulatory filings and support the drug’s use in other IL-5 mediated diseases.
GlaxoSmithKline (GSK) has announced a significant transaction involving the repurchase of its own shares. The company, through its broker Citigroup Global Markets Limited, has acquired 800,000 ordinary shares as part of its existing buyback program. This move is part of a broader strategy to manage its capital structure and potentially enhance shareholder value. The shares will be held in treasury, and the total number of voting rights in the company remains unchanged at 4,142,685,716. This transaction reflects GSK’s ongoing commitment to optimizing its financial operations and maintaining a robust market presence.
GSK has published its Annual Report for the year ending December 31, 2024, which is now available on the company’s website and has been submitted to the UK’s Financial Conduct Authority’s National Storage Mechanism for inspection. The report complies with the FCA’s disclosure requirements, and shareholders who opted for paper communications will receive a hard copy along with the Notice of Annual General Meeting 2025 around March 24, 2025.
GlaxoSmithKline (GSK) has announced a share buyback transaction, purchasing 800,000 of its ordinary shares through Citigroup Global Markets Limited. This purchase is part of GSK’s ongoing buyback program, which aims to manage the company’s capital structure and return value to shareholders. The shares will be held as treasury shares, and the total number of voting rights in the company remains at 4,143,485,716. This move reflects GSK’s strategic focus on optimizing shareholder value and maintaining financial flexibility.
GSK plc announced several transactions involving its senior executives, including the acquisition and sale of shares. Dr. Hal Barron, a Non-Executive Director, acquired American Depositary Shares (ADSs) through reinvestment of dividends, while James Ford, SVP and Group General Counsel, also acquired ADSs and sold ordinary shares. CEO Emma Walmsley gifted ordinary shares to a family member. These transactions reflect the ongoing financial activities and investment strategies of GSK’s leadership, potentially impacting shareholder perceptions and market confidence.
GSK has announced the repurchase of 809,900 of its ordinary shares as part of its ongoing buyback program, with the shares to be held as treasury shares. This move, executed through Citigroup Global Markets Limited, is part of a non-discretionary agreement and reflects GSK’s strategy to manage its capital structure, potentially impacting shareholder value and market perception.
GSK has announced the purchase of 1,001,152 of its own ordinary shares as part of its ongoing buyback program. These shares, bought at a volume-weighted average price of 1,450.90 GBp, will be held as treasury shares, reflecting the company’s strategy to enhance shareholder value and optimize its capital structure.
GSK has finalized its acquisition of IDRx, Inc., a clinical-stage biopharmaceutical company based in Boston, for up to $1.15 billion. This acquisition includes IDRX-42, a promising tyrosine kinase inhibitor designed to address gastrointestinal stromal tumours (GIST) with both primary and secondary KIT mutations. The strategic acquisition is expected to enhance GSK’s oncology pipeline, particularly in the treatment of GIST where current therapies fall short, thereby potentially improving outcomes for patients with this condition.
GSK plc announced the vesting of Deferred Bonus Awards under its 2017 Deferred Annual Bonus Plan for its managers and directors. The awards, granted in 2022, have been exercised as nil-cost options or restricted awards over Ordinary Shares and American Depositary Shares (ADSs), with sales made primarily to cover tax liabilities. This move highlights GSK’s commitment to its remuneration policy and could impact shareholder value by aligning managerial interests with company performance.
GSK announced the vesting details of awards under the 2017 Performance Share Plan for certain managerial personnel. The company achieved significant performance measures over a three-year period ending December 2024, with strong results in shareholder return, sales, profit, and environmental goals, reflecting positively on its strategic objectives. The vested shares for executive directors are now subject to an additional two-year period. This announcement underscores GSK’s operational achievements and commitment to long-term growth, impacting stakeholders favorably with its robust performance metrics.
GSK plc announced a transaction involving its Chief Scientific Officer, Tony Wood. As part of the GlaxoSmithKline Deferred Investment Award Programme, Tony Wood received a cash payment of £247,942.28, equivalent to 17,182.417 notional Ordinary Shares, following the vesting of an award from 2021. This transaction highlights GSK’s compensation strategies and its commitment to rewarding key personnel, potentially impacting stakeholder perceptions of the company’s leadership incentives.
GSK plc announced the granting of conditional share awards under its 2017 Performance Share Plan to senior executives, including executive directors and other key management personnel. These awards, contingent on meeting performance targets over a three-year period from 2025 to 2027, aim to align managerial incentives with company performance goals. The plan’s structure, including additional holding periods for executive directors, underscores GSK’s commitment to long-term growth and shareholder value, with potential implications for executive retention and motivation.
GSK has announced the appointment of Dr. Gavin Screaton as a Non-Executive Director, effective May 1, 2025. Dr. Screaton, an expert in immunology and infectious diseases, will replace Dr. Jesse Goodman, who is retiring after nine years of service. Dr. Screaton’s extensive experience in public health and his current role at the University of Oxford will enhance GSK’s expertise in its core scientific areas. This strategic move is expected to strengthen GSK’s board as it continues to focus on its biopharmaceutical endeavors, potentially impacting its positioning in the industry and its stakeholders.
GSK announced the granting of awards under the 2017 Deferred Annual Bonus Plan to several key executives, including the CEO and CFO, requiring them to defer portions of their bonuses into Ordinary Shares or American Depositary Shares for three years. This move, aligned with shareholder-approved remuneration policies, aims to reinforce commitment to the company’s long-term performance and align the interests of its executives with those of the stakeholders.
GSK announced that the China National Medical Products Administration has accepted the review of its new drug application for Nucala (mepolizumab) as an add-on treatment for COPD with an eosinophilic phenotype. The submission is supported by data from the MATINEE trial, which demonstrated significant reductions in exacerbations among a broad population of COPD patients. If approved, Nucala could become the first approved biologic with monthly dosing for COPD, potentially offering a new treatment option for a significant portion of the 100 million people with COPD in China.
GSK announced that its 5-in-1 meningococcal vaccine, Penmenvy, has received approval from the US FDA for use in individuals aged 10 to 25 years. This vaccine, which protects against the five serogroups of Neisseria meningitidis, aims to improve vaccination rates among US adolescents and young adults, who are at higher risk for invasive meningococcal disease (IMD). The approval positions GSK to enhance its leadership in the US meningococcal vaccine market, with implications for increasing protection against serogroup B, the leading cause of IMD among young people.
GSK plc, a leading pharmaceutical company, announced a series of transactions involving the acquisition of ordinary shares by several of its top executives under the company’s Share Reward Plan. The transactions were conducted on February 11, 2025, at the London Stock Exchange. This move reflects the company’s ongoing commitment to align executive interests with those of shareholders, potentially impacting stakeholder confidence positively.
GSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, including the CEO, and are part of the company’s ongoing employee compensation and incentive strategies. These moves could impact the company’s financials and stakeholder interests by aligning management incentives with long-term company performance.
GSK reported a robust performance for 2024 with a total sales increase of 7% at constant exchange rates, driven by significant growth in specialty medicines despite a decline in vaccine sales. The company faced a notable decline in total operating profit and EPS primarily due to a substantial charge related to Zantac litigation. However, GSK’s specialty medicines portfolio showed strong momentum, bolstered by advancements in its pipeline and strategic acquisitions. Looking ahead, GSK anticipates growth in turnover, core operating profit, and EPS for 2025, supported by its R&D investments and a planned share buyback program. The company has also raised its 2031 sales outlook, underscoring its strategic focus on long-term growth and shareholder returns.
GSK plc has announced its total voting rights and capital as of January 31, 2025. The company has an issued share capital of 4,315,116,636 shares, with 169,171,155 shares held in treasury, resulting in 4,145,945,481 voting rights. This information is crucial for shareholders to determine any changes to their interest in the company, in compliance with the Financial Conduct Authority’s rules.
GSK announced that its new drug applications for depemokimab have been accepted for review in China and Japan for the treatment of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, depemokimab would be the first ultra-long-acting biologic with a six-month dosing schedule, offering significant benefits in terms of patient adherence and health system efficiency. This follows positive results from the SWIFT and ANCHOR trials, which demonstrated the drug’s efficacy in reducing exacerbations and nasal polyp size. The acceptance of these applications could strengthen GSK’s position in the respiratory market, providing a new treatment option for conditions driven by type 2 inflammation.
GSK has announced that the European Medicines Agency has accepted their application for depemokimab, a new ultra-long-acting biologic for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, it will be the first of its kind with a 6-month dosing schedule. The submission is supported by positive results from the SWIFT and ANCHOR trials, which demonstrated depemokimab’s effectiveness in reducing asthma exacerbations and nasal polyp size. This innovation could significantly impact the treatment landscape by providing sustained disease inhibition with fewer doses, thereby addressing patient adherence challenges and reducing healthcare burdens.
GSK has announced that the European Medicines Agency has accepted its new prefilled syringe presentation of Shingrix, a vaccine for shingles, for review. This development is expected to simplify vaccine administration, eliminating the need for reconstitution of separate vials and potentially expanding its use among healthcare professionals. The acceptance follows a similar file acceptance by the US FDA earlier this month, emphasizing GSK’s commitment to enhancing adult immunization globally. The prefilled syringe aims to maintain the same efficacy, providing a more convenient option to address the significant healthcare burden of shingles, which affects up to one in three adults globally.
GSK announced that the European Commission has expanded the approval for Jemperli (dostarlimab) combined with chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This expansion specifically includes those with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumors, significantly broadening treatment options for around 75% of endometrial cancer cases. This approval came following the RUBY Part 1 trial, which demonstrated a substantial improvement in overall survival rates compared to chemotherapy alone, marking a significant advancement in the treatment landscape for endometrial cancer.
GSK plc announced transactions involving the acquisition of ordinary shares by key personnel, including David Redfern, President of Corporate Development, and Victoria Whyte, Company Secretary. These acquisitions were facilitated by the reinvestment of dividends paid to shareholders on January 9, 2025, and were conducted on the London Stock Exchange. The transactions reflect ongoing financial activities within the company, potentially impacting shareholder value and market perceptions of GSK’s financial health.
GSK plc has announced an increase in notional interest in ordinary shares and American Depositary Shares due to the reinvestment of dividends from its Deferred Annual Bonus Plan. The transactions, involving key executives including CEO Emma Walmsley and CFO Julie Brown, were conducted on January 14, 2025, at both the London and New York Stock Exchanges. This move could potentially enhance shareholder value and reflect the company’s commitment to reinvesting in its own stock, affecting its market positioning and stakeholder interests.
GSK has announced the acquisition of ordinary shares by several of its senior executives as part of the Company’s Share Reward Plan. This transaction, conducted on January 10, 2025, at the London Stock Exchange, involved key personnel including the CEO, CFO, and other senior vice presidents, highlighting their confidence in the company’s strategic direction and future growth prospects.
GSK plc has announced the acquisition of ordinary shares by several top executives, including CEO Emma Walmsley and Chief Commercial Officer Luke Miels, following the reinvestment of dividends paid to shareholders on January 9, 2025. This move, conducted on the London Stock Exchange, highlights the company’s commitment to aligning the interests of its leadership with those of its shareholders, potentially reinforcing market confidence in GSK’s strategic direction.
GSK has announced its agreement to acquire IDRx, Inc. for up to $1.15 billion, including a $1 billion upfront payment. This acquisition will enhance GSK’s portfolio in gastrointestinal cancers by adding IDRX-42, a selective KIT tyrosine kinase inhibitor designed to treat gastrointestinal stromal tumors (GIST). IDRX-42 has shown promising results in targeting key KIT mutations, offering potential improvements over existing therapies. The transaction aligns with GSK’s strategy to acquire assets addressing validated targets and unmet medical needs, reinforcing its position in the oncology sector.
GSK has announced that the US FDA has accepted the review of a new prefilled syringe presentation for its shingles vaccine, Shingrix. This new format aims to simplify the administration process for healthcare professionals and is expected to be decided upon by June 20, 2025. This development represents a significant regulatory step for GSK’s Shingrix, which has been a vital component of shingles prevention since 2017, and highlights the company’s commitment to innovation in its product offerings.
GSK announced that the US FDA has accepted its application for a new prefilled syringe presentation of Shingrix, its shingles vaccine. This development is seen as a significant step for GSK, as it simplifies vaccine administration for healthcare professionals and enhances the company’s product offerings in the immunization market. Shingrix is already a proven product with over 90 million doses distributed in the US, underscoring GSK’s strong presence in the shingles prevention market.
GSK has announced that its B7-H3-targeted antibody-drug conjugate, GSK’227, has received Breakthrough Therapy Designation from the US FDA for treating relapsed or refractory osteosarcoma. This designation, based on early promising data, highlights the urgent need for effective treatments in this area, as current options are limited following progression on two prior therapies. The designation is supported by data from the ARTEMIS-002 study, a clinical trial evaluating the drug’s efficacy and safety. This development positions GSK’227 as a potential breakthrough in treating this rare bone cancer, enhancing GSK’s standing in the oncology sector and offering hope to patients with limited treatment options.
GSK plc has announced a series of transactions involving the purchase of ordinary shares and American Depositary Shares (ADSs) by its non-executive directors and persons closely associated with them. These transactions, conducted on the London Stock Exchange and New York Stock Exchange, reflect internal confidence in the company’s future prospects. The purchases may have implications for GSK’s market positioning and stakeholder engagement, signaling robust internal support for the company’s strategic direction.
GSK has made an application to the Financial Conduct Authority and the London Stock Exchange for the admission of 700,000 Ordinary Shares reserved under its Share Save Plan 2012 to the Official List. The effective admission date for these shares, which will hold the same rights as existing shares, is expected to be December 23, 2024. This move indicates GSK’s ongoing commitment to its employee investment programs and may enhance liquidity in its stock, potentially impacting investor relations positively.
GSK announced that the FIRST-ENGOT-OV44 phase III trial for advanced ovarian cancer has met its primary endpoint of progression-free survival. The trial showed that adding Jemperli (dostarlimab) to standard chemotherapy and Zejula (niraparib) maintenance resulted in a statistically significant improvement in progression-free survival compared to the active comparator arm. While the key secondary endpoint of overall survival did not meet statistical significance, further analyses are ongoing. The results of the trial could strengthen GSK’s position in the oncology market, particularly in gynecologic cancers, and provide new hope for patients suffering from advanced ovarian cancer.
GSK announced that its drug Jemperli (dostarlimab) has received the US FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, based on data showing a 100% complete clinical response in a trial of 42 patients. This designation may expedite the drug’s development and review, potentially shifting the treatment paradigm for this cancer type, which currently involves significant quality-of-life impacts from standard care procedures. The ongoing AZUR-1 trial seeks to confirm these promising results, highlighting a possible substantial advancement in therapy options for patients.
GSK announced that its B7-H3-targeted antibody-drug conjugate, GSK’227, has received Priority Medicines (PRIME) Designation from the European Medicines Agency for relapsed extensive-stage small-cell lung cancer, based on promising preliminary clinical data. This designation, which follows a similar Breakthrough Therapy Designation from the US FDA, highlights the potential of GSK’227 to address significant unmet medical needs in a cancer subtype with poor prognosis and limited treatment options. The designation supports GSK’s efforts to accelerate the drug’s development, enhancing its position in the oncology market and offering hope to stakeholders seeking better treatment solutions in this challenging area.
GSK announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended expanding the approval of Jemperli (dostarlimab) with chemotherapy for first-line treatment of adult patients with advanced or recurrent endometrial cancer. If approved, this expansion would include the majority of endometrial cancer cases, potentially transforming treatment options and improving patient outcomes. The decision is expected in the first quarter of 2025, and is based on promising data from the phase III RUBY trial, showcasing significant benefits in progression-free and overall survival.
In a recent transaction notification, GSK plc revealed that several key executives, including CEO Emma Walmsley and CFO Julie Brown, have acquired ordinary shares under the company’s Share Reward Plan. Each transaction involved the acquisition of 18 ordinary shares at a price of £13.9239 per share, conducted on December 10, 2024, at the London Stock Exchange. This move reflects the company’s commitment to aligning executive interests with shareholder value and may enhance stakeholder confidence in the company’s future prospects.
GSK’s latest trial results reveal that Blenrep, in combination with other drugs, significantly reduces the risk of death in multiple myeloma patients by 42% compared to the standard treatment. These findings highlight Blenrep’s potential to become a new standard of care, with regulatory reviews underway in major markets. Investors might find GSK’s advancements in this treatment promising for the company’s growth and stock performance.
GlaxoSmithKline (GSK) has announced that the FDA has accepted its submission for Nucala, a potential new treatment for chronic obstructive pulmonary disease (COPD), marking it as the first biologic with monthly dosing for COPD patients. The submission is bolstered by data from the MATINEE study, which shows Nucala’s efficacy in significantly reducing exacerbations in COPD patients. This development could impact the healthcare market, offering relief to millions affected by COPD and potentially alleviating the financial strain on healthcare systems.
GSK has extended its collaboration with Chongqing Zhifei Biological Products to distribute its shingles vaccine, Shingrix, in China until 2034, while also exploring a new partnership on a respiratory syncytial virus vaccine. This strategic move could potentially generate £2.3 billion for GSK from Zhifei’s Shingrix purchases over the next six years. The collaboration aims to reach over 500 million people in China, enhancing vaccine availability in a rapidly growing market.